Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pomalidomide - Celgene Corporation

Drug Profile

Pomalidomide - Celgene Corporation

Alternative Names: Actimid; CC-4047; CDC-394; Imnovid; Pomalidomide-Celgene; Pomalyst

Latest Information Update: 04 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Celgene Corporation
  • Developer Celgene Corporation; Dana-Farber Cancer Institute; Sarah Cannon Research Institute; University of Texas M. D. Anderson Cancer Center
  • Class Anti-inflammatories; Antineoplastics; Phthalimides; Piperidones; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Immunomodulators; Interleukin 6 inhibitors; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma; Myelofibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple myeloma
  • Phase III Myelofibrosis
  • Phase II Brain cancer; Systemic scleroderma
  • Phase I/II Amyloid light-chain amyloidosis
  • Clinical Phase Unknown Kaposi's sarcoma
  • No development reported Pancreatic cancer; Sickle cell anaemia; Small cell lung cancer; Waldenstrom's macroglobulinaemia

Most Recent Events

  • 04 Nov 2019 Bristol-Myers Squibb plans a phase I/II trial for Multiple Myeloma (Combination therapy, Late-stage disease) in December 2019 (NCT04150965)
  • 23 Jul 2019 Celgene completes a phase I trial for Multiple myeloma (Combination therapy, Second-line therapy or greater) in USA (PO) (NCT01497093)
  • 10 Jul 2019 Health Canada approves pomalidomide in combination with bortezomib and dexamethasone for treatment of Multiple myeloma in Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top